Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Edelmann

Showing results (161-170 of 218) with videos related to

Pageof 22
Sort By:
Scandinavian Journal of Medicine & Science in Sports|January 17, 2026
Effects of Exercise Duration and Intensity on Maximal Exercise Capacity Over 6 Months in Coronary Heart Disease and Type 2 Diabetes-A Secondary Analysis of the LeIKDTrialFelix Gass, Sophia M Dinges, Isabel Fegers-Wustrow, et al.
European Journal of Heart Failure|July 6, 2022
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trialMichele Senni, Wendimagegn G Alemayehu, David Sim, et al.
European Journal of Heart Failure|April 17, 2023
A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trialMasatake Kobayashi, Olivier Huttin, João Pedro Ferreira, et al.
European Journal of Preventive Cardiology|October 25, 2024
Comparison of exercise training modalities and change in peak oxygen consumption in heart failure with preserved ejection fraction: a secondary analysis of the OptimEx-Clin trialStephan Mueller, Marina Kabelac, Isabel Fegers-Wustrow, et al.
ESC Heart Failure|February 25, 2018
Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR studyHans-Dirk Düngen, Verena Tscholl, Danilo Obradovic, et al.
European Journal of Heart Failure|September 13, 2023
Supervised exercise training in patients with advanced heart failure and left ventricular assist device: A multicentre randomized controlled trial (Ex-VAD trial)Anna Feuerstein, Felix Schoenrath, Evgeny Belyavskiy, et al.
European Heart Journal. Cardiovascular Imaging|October 5, 2017
Lower limit of normality and clinical relevance of left ventricular early diastolic strain rate for the detection of left ventricular diastolic dysfunctionDaniel A Morris, Masaaki Takeuchi, Satoshi Nakatani, et al.
ESC Heart Failure|December 1, 2021
NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trialsStefanie M Werhahn, Christian Becker, Meinhard Mende, et al.
ESC Heart Failure|May 6, 2021
Serum creatinine and cystatin C-based estimates of glomerular filtration rate are misleading in acute heart failureJutta S Swolinsky, Niklas P Nerger, David M Leistner, et al.
International Journal of Cardiology. Heart & Vasculature|July 14, 2021
Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stentingLisa Riesinger, Claudia Strobl, David M Leistner, et al.
Pageof 22

Showing results (161-170 of 218) with videos related to

Sort By:
Pageof 22
Scandinavian Journal of Medicine & Science in Sports|January 17, 2026
Effects of Exercise Duration and Intensity on Maximal Exercise Capacity Over 6 Months in Coronary Heart Disease and Type 2 Diabetes-A Secondary Analysis of the LeIKDTrialFelix Gass, Sophia M Dinges, Isabel Fegers-Wustrow, et al.
European Journal of Heart Failure|July 6, 2022
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trialMichele Senni, Wendimagegn G Alemayehu, David Sim, et al.
European Journal of Heart Failure|April 17, 2023
A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trialMasatake Kobayashi, Olivier Huttin, João Pedro Ferreira, et al.
European Journal of Preventive Cardiology|October 25, 2024
Comparison of exercise training modalities and change in peak oxygen consumption in heart failure with preserved ejection fraction: a secondary analysis of the OptimEx-Clin trialStephan Mueller, Marina Kabelac, Isabel Fegers-Wustrow, et al.
ESC Heart Failure|February 25, 2018
Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR studyHans-Dirk Düngen, Verena Tscholl, Danilo Obradovic, et al.
European Journal of Heart Failure|September 13, 2023
Supervised exercise training in patients with advanced heart failure and left ventricular assist device: A multicentre randomized controlled trial (Ex-VAD trial)Anna Feuerstein, Felix Schoenrath, Evgeny Belyavskiy, et al.
European Heart Journal. Cardiovascular Imaging|October 5, 2017
Lower limit of normality and clinical relevance of left ventricular early diastolic strain rate for the detection of left ventricular diastolic dysfunctionDaniel A Morris, Masaaki Takeuchi, Satoshi Nakatani, et al.
ESC Heart Failure|December 1, 2021
NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trialsStefanie M Werhahn, Christian Becker, Meinhard Mende, et al.
ESC Heart Failure|May 6, 2021
Serum creatinine and cystatin C-based estimates of glomerular filtration rate are misleading in acute heart failureJutta S Swolinsky, Niklas P Nerger, David M Leistner, et al.
International Journal of Cardiology. Heart & Vasculature|July 14, 2021
Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stentingLisa Riesinger, Claudia Strobl, David M Leistner, et al.
Pageof 22